[go: up one dir, main page]

DK3774838T3 - Lixisenatidsyntese med capping - Google Patents

Lixisenatidsyntese med capping Download PDF

Info

Publication number
DK3774838T3
DK3774838T3 DK19715517.9T DK19715517T DK3774838T3 DK 3774838 T3 DK3774838 T3 DK 3774838T3 DK 19715517 T DK19715517 T DK 19715517T DK 3774838 T3 DK3774838 T3 DK 3774838T3
Authority
DK
Denmark
Prior art keywords
lixisenate
capping
synthesis
lixisenate synthesis
Prior art date
Application number
DK19715517.9T
Other languages
English (en)
Inventor
Bernd Henkel
Tobias Metzenthin
Manfred Gerken
Wolfgang Fiedler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62002530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3774838(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK3774838T3 publication Critical patent/DK3774838T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/063—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/062—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha- or omega-carboxy functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/066—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amido functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19715517.9T 2018-04-10 2019-04-10 Lixisenatidsyntese med capping DK3774838T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166551 2018-04-10
PCT/EP2019/059090 WO2019197469A1 (en) 2018-04-10 2019-04-10 Lixisenatide synthesis with capping

Publications (1)

Publication Number Publication Date
DK3774838T3 true DK3774838T3 (da) 2022-10-31

Family

ID=62002530

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19715517.9T DK3774838T3 (da) 2018-04-10 2019-04-10 Lixisenatidsyntese med capping

Country Status (15)

Country Link
US (1) US11028123B2 (da)
EP (1) EP3774838B1 (da)
JP (1) JP7332620B2 (da)
KR (1) KR102727918B1 (da)
CN (1) CN112218876B (da)
AU (1) AU2019250362A1 (da)
BR (1) BR112020020647A2 (da)
CA (1) CA3096495A1 (da)
DK (1) DK3774838T3 (da)
ES (1) ES2928207T3 (da)
HU (1) HUE059777T2 (da)
IL (1) IL277836A (da)
MX (1) MX2020010715A (da)
SG (1) SG11202010016QA (da)
WO (1) WO2019197469A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3774838T3 (da) 2018-04-10 2022-10-31 Sanofi Aventis Deutschland Lixisenatidsyntese med capping

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
PA8442401A1 (es) 1996-12-09 2000-05-24 Guilford Pharm Inc Inhibidores polipropilos de ciclofilina
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
NZ504256A (en) 1997-11-14 2003-01-31 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for treating diabetes
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
JP2002521319A (ja) * 1998-07-23 2002-07-16 メタファー・インコーポレイテッド ポリヒドロキサメートおよびそのアナログのライブラリー
GB9818730D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
WO2001072412A1 (de) 2000-03-28 2001-10-04 Laser- Und Medizin-Technologie Gmbh Berlin Verfahren und vorrichtung zum aufbau und untersuchung von substanzbibliotheken
FR2813794B1 (fr) * 2000-09-08 2003-01-24 Pasteur Institut Procede de couplage, en solution, entre un peptide et un vecteur lipophile et ses applications
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
MXPA05003335A (es) 2002-10-02 2005-07-05 Zealand Pharma As Compuestos de exendina-4 estabilizados.
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20050176079A1 (en) 2004-02-09 2005-08-11 Chu Yong L. Polypeptide bioconjugates, methods of making the bioconjugates and assays employing the bioconjugates
US20080019911A1 (en) 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
CN101282991A (zh) 2005-05-26 2008-10-08 布里斯托尔-迈尔斯斯奎布公司 N-端修饰的胰高血糖素样肽-1受体调节剂
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
US8354392B2 (en) 2005-07-06 2013-01-15 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
CN101357938B (zh) 2007-07-31 2013-07-03 周逸明 固相多肽合成Exenatide的制备方法
DK2237799T3 (da) 2008-02-01 2019-06-11 Ascendis Pharma As Prodrug omfattende en selv-spaltbar linker
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
BRPI1008039A2 (pt) * 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
MX2013006304A (es) 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
RU2013135175A (ru) * 2011-01-03 2015-02-10 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
US20130289241A1 (en) * 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
CN104583233B (zh) 2012-06-21 2018-10-23 印第安纳大学研究及科技有限公司 表现出gip受体活性的胰高血糖素的类似物
CN103163233B (zh) 2012-07-12 2014-06-25 海南合瑞制药股份有限公司 固相合成胸腺肽α1的28肽阶段的缺失肽及检测方法
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2917234B1 (en) 2012-11-06 2020-12-02 Les Hôpitaux Universitaires de Genève Mimetic peptides
CA2894765A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
CN103819553A (zh) * 2013-12-27 2014-05-28 苏贤斌 一种使用固相和液相组合技术制备利西拉来的方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN104211801A (zh) * 2014-07-25 2014-12-17 杭州诺泰制药技术有限公司 一种制备利西拉来的方法
WO2016029324A1 (en) * 2014-08-29 2016-03-03 Rsem, Limited Partnership Azasulfurylpeptide-based cd36 modulators and uses thereof
CN104844706B (zh) 2015-06-10 2018-08-03 成都圣诺生物科技股份有限公司 一种合成利西拉来的方法
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
EP3368556B1 (en) * 2015-10-28 2024-04-10 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
EP3433267B1 (en) * 2016-03-23 2022-08-24 Bachem Holding AG Method for preparing glucagon-like peptides
US20170313740A1 (en) 2016-04-28 2017-11-02 C S Bio Co. Methods of preparing peptides
TW201821434A (zh) 2016-10-10 2018-06-16 法商賽諾菲公司 製備包含親脂性修飾的離胺酸側鏈的肽的方法
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
SG11202010017SA (en) * 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Method for cleavage of solid phase-bound peptides from the solid phase
DK3774838T3 (da) 2018-04-10 2022-10-31 Sanofi Aventis Deutschland Lixisenatidsyntese med capping

Also Published As

Publication number Publication date
EP3774838B1 (en) 2022-08-10
AU2019250362A1 (en) 2020-11-26
US11028123B2 (en) 2021-06-08
CA3096495A1 (en) 2019-10-17
MX2020010715A (es) 2021-01-08
BR112020020647A2 (pt) 2021-02-23
JP2021521144A (ja) 2021-08-26
CN112218876B (zh) 2024-10-15
JP7332620B2 (ja) 2023-08-23
WO2019197469A1 (en) 2019-10-17
KR102727918B1 (ko) 2024-11-11
ES2928207T3 (es) 2022-11-16
SG11202010016QA (en) 2020-11-27
KR20200142032A (ko) 2020-12-21
CN112218876A (zh) 2021-01-12
HUE059777T2 (hu) 2022-12-28
EP3774838A1 (en) 2021-02-17
IL277836A (en) 2020-11-30
US20190330263A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CA185236S (fr) Bouteille
CA185232S (fr) Bouteille
CA185234S (fr) Bouteille
CA185233S (fr) Bouteille
DK3774838T3 (da) Lixisenatidsyntese med capping
CA185986S (fr) Bouteille
CA185235S (fr) Bouteille
UA39467S (uk) Пляшка
UA38767S (uk) Пляшка
UA38770S (uk) Пляшка
UA38763S (uk) Пляшка
UA38762S (uk) Пляшка
UA38761S (uk) Пляшка
UA38765S (uk) Пляшка
UA38764S (uk) Пляшка
UA38769S (uk) Пляшка
UA38766S (uk) Пляшка
UA38768S (uk) Пляшка
UA38483S (uk) Пляшка
UA38484S (uk) Пляшка
UA38415S (uk) Пляшка
UA39132S (uk) Пляшка
UA39133S (uk) Пляшка
TH1802004224S (th) ขวด
TH191091S (th) ขวด